Macrophages contribute to liver repair after monocrotaline-induced liver injury via SDF-1/CXCR4.

C-X-C chemokine receptor type 4 liver repair macrophage monocrotaline stromal cell-derived factor 1

Journal

Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 27 11 2020
accepted: 18 02 2021
entrez: 14 5 2021
pubmed: 15 5 2021
medline: 15 5 2021
Statut: ppublish

Résumé

Monocrotaline (MCT) administration induces liver injury in rodents that mimics the pathology of human sinusoidal obstruction syndrome. MCT-induced SOS models are used to investigate the mechanism of injury and optimize treatment strategies. However, the processes underlying liver repair are largely unknown. Specifically, the role of macrophages, the key drivers of liver repair, has not been elucidated. The current study aimed to examine the role of macrophages in the repair of MCT-induced liver injury in male C57/BL6 mice. Maximal liver injury occurred at 48 h post-MCT treatment, followed by repair at 120 h post-treatment. Immunofluorescence analysis revealed that CD68

Identifiants

pubmed: 33986833
doi: 10.3892/etm.2021.10100
pii: ETM-0-0-10100
pmc: PMC8112113
doi:

Types de publication

Journal Article

Langues

eng

Pagination

668

Informations de copyright

Copyright: © Otaka et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Am J Physiol Gastrointest Liver Physiol. 2016 Aug 1;311(2):G203-9
pubmed: 27313175
FEBS Lett. 2002 Sep 11;527(1-3):255-62
pubmed: 12220670
J Gastroenterol. 2014 Mar;49(3):455-69
pubmed: 23982810
Nat Med. 2006 May;12(5):557-67
pubmed: 16648859
Arch Toxicol. 2011 Sep;85(9):1079-89
pubmed: 21279329
Cells. 2020 May 21;9(5):
pubmed: 32455728
Biomed Pharmacother. 2019 Sep;117:109067
pubmed: 31176171
Toxicol Sci. 2011 Mar;120(1):218-29
pubmed: 21135413
J Exp Med. 2018 Jan 2;215(1):303-318
pubmed: 29203538
PLoS One. 2015 Jul 02;10(7):e0131445
pubmed: 26133989
Hepatology. 1999 Jun;29(6):1779-91
pubmed: 10347121
Toxicol Appl Pharmacol. 2019 Oct 15;381:114733
pubmed: 31470032
Nat Rev Immunol. 2017 May;17(5):306-321
pubmed: 28317925
Hepatol Res. 2015 Jul;45(7):794-803
pubmed: 25163538
FASEB J. 2020 Apr;34(4):5610-5627
pubmed: 32112485
Hepatology. 2009 Jun;49(6):2055-67
pubmed: 19434726
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):378-85
pubmed: 27038846
Toxicol Pathol. 2005;33(1):41-51
pubmed: 15805055
J Hepatol. 2018 Jul;69(1):110-120
pubmed: 29458169
Semin Liver Dis. 2002 Feb;22(1):27-42
pubmed: 11928077
Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68
pubmed: 19766729
Hepatology. 2009 Nov;50(5):1617-24
pubmed: 19725107
J Clin Invest. 2014 Nov;124(11):4882-94
pubmed: 25271626
J Clin Invest. 2003 Jul;112(2):160-9
pubmed: 12865405
Am J Physiol Gastrointest Liver Physiol. 2016 May 1;310(9):G739-46
pubmed: 26939868
Toxicol Appl Pharmacol. 2012 Feb 15;259(1):104-14
pubmed: 22206755
Am J Physiol Gastrointest Liver Physiol. 2015 Apr 15;308(8):G702-9
pubmed: 25721302
Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G1045-52
pubmed: 12584111
PLoS One. 2014 Aug 27;9(8):e105533
pubmed: 25162491

Auteurs

Fumisato Otaka (F)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Yoshiya Ito (Y)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Shuji Nakamoto (S)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Nobuyuki Nishizawa (N)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Tetsuya Hyodo (T)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Plastic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Kanako Hosono (K)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Masataka Majima (M)

Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Department of Medical Therapeutics, Kanagawa Institute of Technology, Atsugi, Kanagawa 243-0292, Japan.

Wasaburo Koizumi (W)

Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Hideki Amano (H)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.
Department of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Classifications MeSH